Acute Kidney Injury (AKI) Disease Treatment Market Size, Share, Opportunities, And Trends By Component (Treatment (Drug Type (Isotonic Solution, Antibiotic, Others)), Dialysis, Diagnosis (Urine Tests, Blood Tests, Glomerular Filtration Rate (GFR), Imaging tests, Kidney Biopsy)), By Type Of RRT (Continuous, Intermittent), And By Geography - Forecasts From 2023 To 2028

The acute kidney injury (AKI) disease treatment market is predicted to grow at a CAGR of 7.50% from US$2.004 billion in 2025 to US$2.875 billion by 2030.

The global market for acute renal injury treatment is significantly influenced by the rising incidence of acute kidney damage. The National Kidney Foundation estimates that kidney illnesses impact about 37 million people in the US. Kidney injury risk has increased as a result of an aging population, poor diet, and heavy alcohol use. Acetaminophen and other drug overdoses, hepatitis, autoimmune disorders, and metabolic diseases are other causes contributing to the market's explosive expansion. Additionally, it is projected that rising healthcare costs and government measures to improve the healthcare system will boost market revenue. However, the market expansion is being hampered by the high cost of dialysis services and the low compliance from patients for long-term treatment plans.

What are the drivers of the acute kidney injury disease treatment market?

• Increase in lifestyle-related diseases and technological advancements.

Acute kidney injury results in sudden and temporary loss of the function of the kidney. This could occur due to several underlying diseases like diabetes and high blood pressure. A slew of diseases is cropping up due to the changing lifestyles of people. Some of the prominent examples are diabetes, obesity, hypertension, and other liver or kidney-related diseases. The World Health Organisation estimates that 60% of the variables affecting a person's health and quality of life are related to their way of living. People's health is being impacted by processed and junk food as well as poor eating habits. Additionally, a lack of exercise and movement increases the risk of dyspepsia and subsequent acute renal damage.

People are developing addictions to drugs, alcohol, and smoking, all of which have detrimental effects on their health. Lack of physical movement and exercise is also increasing the likelihood of indigestion, and consequent acute kidney injuries. People are getting addicted to alcohol, smoking, and drugs which also have adverse implications for their health. For instance, the International Society of Nephrology estimates that there are over 13.3 million cases of acute renal damage each year throughout the world. Globally, acute renal damage also results in 1.7 million deaths each year. AKI is present in about 1% of hospitalized patients in the United States.

Moreover, AKI occurs in more than 50% of patients in intensive care units (ICU) and occurs within 30 days of surgery in about 1% of general surgical cases. Additionally, according to the 2023 report of the National Institute of Diabetes and Digestive and Kidney Diseases, 2 in 1000 Americans have end-stage kidney illness, with 71% relying on dialysis and 29% receiving a kidney transplant. The need for precise and effective treatment is growing along with the prevalence of renal disorders.

• Various government initiatives.

Government efforts to speed up healthcare innovation are also accelerating the market expansion in the US. The National Artificial Intelligence Research Resource Task Force was established in June 2021 as a result of an announcement made by the National Science Foundation and the White House Office of Science and Technology Policy. This task force develops a roadmap for the expansion of educational resources and essential tools that will promote Al innovation across the country.

Moreover, the industry's leading players are concentrating on the development of acute renal injury therapies, which is anticipated to propel the growth of the worldwide acute kidney injury treatment market during the forecast period. The first of its type Carpediem system is recommended for use in patients needing hemodialysis or hemofiltration therapy due to acute renal damage or fluid overload. It is designed to give patients who weigh between 2.5 and 10 kilograms continuous renal replacement treatment.

Additionally, in September 2021, Sentien Biotechnologies, Inc., a clinical-stage technological advancement company developing novel cell therapy methods, announced a collaboration with the biomedical field Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services Assistant Secretary for Preparedness and Response, to test Sentien's ex vivo cell therapy, SBI-101, in patients with acute kidney injuries.

• Growing demand for continuous renal replacement therapy (CRRT).

The growth of the market in this segment is being driven by rising investments by key players in improving the performance, reliability, and safety of systems used in this type of Renal Replacement Therapy (RRT). Unlike intermittent RRT, continuous dialysis involves the removal of water and waste from the blood takes place at a slow and steady rate which reduces the risk of this removal being poorly tolerated by hemodynamically unstable patients. Although this type of RRT is better suited for the treatment of AKI, their higher cost continues to be a major factor hindering their adoption across many economies where the affordability of expensive medical procedures is still a goal.

Technological advancements are benefiting the market as improvements in CRRT machines, hemofilters, and monitoring systems have enhanced the efficiency, safety, and ease of use of the therapy. These technological advancements have contributed to the growth and adoption of CRRT as a preferred treatment modality for AKI. The availability and accessibility of healthcare infrastructure, including specialized intensive care units (ICUs) and renal care facilities, play a significant role in the growth of CRRT for AKI treatment. Adequate infrastructure ensures that healthcare providers can effectively deliver continuous renal replacement therapy to critically ill patients in need.

The Acute kidney injury disease treatment market is segmented into five regions worldwide:

The North American AKI disease treatment market has been segmented into the United States, Canada, and Mexico and is estimated to grow at a significant CAGR during the forecast period. The high prevalence of diabetes in the U.S. is increasing the number of people with acute kidney injury. According to the Centers for Disease Control and Prevention (CDC), AKI is a significant public health problem in the United States, affecting over 500,000 people each year and resulting in more than 100,000 deaths. AKI is also associated with increased healthcare costs, with hospitalizations for AKI costing an estimated $10 billion annually in the US. Moreover, there is increasing adoption of innovative treatment options, such as renal replacement therapies (RRTs), which include hemodialysis and peritoneal dialysis. These treatments are becoming more widely available and affordable, allowing more patients to access the care they need.

Furthermore, the prevalence of the various causes of AKI can guide future research and development in the AKI treatment market. For instance, given that urinary tract obstruction is a significant cause of AKI, there may be an opportunity for drug developers to focus on developing therapies that address this condition, especially in older men with benign prostatic hypertrophy.

Acute Kidney Injury Disease Treatment Market Key Developments:

• In September 2024, Travere Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted full approval to FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression.

The Acute kidney injury disease treatment market is segmented and analyzed as follows:

• By Component
  • Treatment
    • Drug Type
    • Isotonic Solution
    • Antibiotic
    • Others
    • Dialysis
  • Diagnosis
    • Urine Test
    • Blood Test
    • Glomerular Filtration Rate (GFR)
    • Imaging Test
    • Biopsy
• By RRT
  • Continuous
  • Intermittent
• By Geography
  • North America
    • By Component
    • By Type of RRT
    • By Country
      • USA
      • Canada
      • Mexico
  • South America
    • By Component
    • By Type of RRT
    • By Country
      • Brazil
      • Argentina
      • Others
  • Europe
    • By Component
    • By Type of RRT
    • By Country
      • Germany
      • France
      • United Kingdom
      • Spain
      • Others
  • Middle East and Africa
    • By Component
    • By Type of RRT
    • By Country
      • Saudi Arabia
      • UAE
      • Israel
      • Others
  • Asia Pacific
    • By Component
    • By Type of RRT
    • By Country
      • China
      • Japan
      • South Korea
      • India
      • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Supplier

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY COMPONENT

5.1. Introduction

5.2. Treatment

5.2.1. Drug Type

5.2.1.1. Isotonic Solution

5.2.1.2. Antibiotic

5.2.1.3. Others

5.2.2. Dialysis

5.3. Diagnosis

5.3.1. Urine Test

5.3.2. Blood Test

5.3.3. Glomerular Filtration Rate (GFR)

5.3.4. Imaging Test

5.3.5. Biopsy

6. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY TYPE OF RRT

6.1. Introduction

6.2. Continuous

6.3. Intermittent

7. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. By Component

7.2.2. By Type of RRT

7.2.3. By Country

7.2.3.1. USA

7.2.3.2. Canada

7.2.3.3. Mexico

7.3. South America

7.3.1. By Component

7.3.2. By Type of RRT

7.3.3. By Country

7.3.3.1. Brazil

7.3.3.2. Argentina

7.3.3.3. Others

7.4. Europe

7.4.1. By Component

7.4.2. By Type of RRT

7.4.3. By Country

7.4.3.1. Germany

7.4.3.2. France

7.4.3.3. United Kingdom

7.4.3.4. Spain

7.4.3.5. Others

7.5. Middle East and Africa

7.5.1. By Component

7.5.2. By Type of RRT

7.5.3. By Country

7.5.3.1. Saudi Arabia

7.5.3.2. UAE

7.5.3.3. Israel

7.5.3.4. Others

7.6. Asia Pacific

7.6.1. By Component

7.6.2. By Type of RRT

7.6.3. By Country

7.6.3.1. China

7.6.3.2. Japan

7.6.3.3. South Korea

7.6.3.4. India

7.6.3.5. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. Exponential Biotherapies, Inc.

9.2. Nikkiso America, Inc.

9.3. Am-Pharma

9.4. Renalguard Solutions, Inc.

9.5. Angion Biomedica Corp.

9.6. Thrasos Therapeutics Inc.

9.7. Atoxbio

9.8. Sentien Biotechnologies, Inc 

Exponential Biotherapies, Inc.

Nikkiso America, Inc.

Am-Pharma

Renalguard Solutions, Inc.

Angion Biomedica Corp.

Thrasos Therapeutics Inc.

Atoxbio

Sentien Biotechnologies, Inc